Literature DB >> 28743043

Neurotrophy and immunomodulation of induced neural stem cell grafts in a mouse model of closed head injury.

Mou Gao1, Hui Yao2, Qin Dong3, Yan Zhang2, Yang Yang2, Yihua Zhang4, Zhijun Yang2, Minhui Xu5, Ruxiang Xu6.   

Abstract

Closed head injury (CHI) usually results in severe and permanent neurological impairments, which are caused by several intertwined phenomena, such as cerebral edema, blood-brain barrier (BBB) disruption, neuronal loss, astroglial scarring and inflammation. We previously reported that induced neural stem cells (iNSCs), similar to neural stem cells (NSCs), can accelerate neurological recovery in vivo and produce neurotrophic factors in vitro. However, the effects of iNSC neurotrophy following CHI were not determined. Moreover, whether iNSCs have immunomodulatory properties is unknown. Mouse models of CHI were established using a standardized weight-drop device and assessed by neurological severity score (NSS). Although these models fail to mimic the complete spectrum of human CHI, they reproduce impairment in neurological function observed in clinical patients. Syngeneic iNSCs or NSCs were separately transplanted into the brains of CHI mice at 12h after CHI. Neurological impairment post-CHI was evaluated by several tests. Animals were sacrificed for morphological and molecular biological analyses. We discovered that iNSC administration promoted neurological functional recovery in CHI mice and reduced cerebral edema, BBB disruption, cell death and astroglial scarring following trauma. Implanted iNSCs could up-regulate brain-derived neurotrophic factor (BDNF) and glial-derived neurotrophic factor (GDNF) levels to support the survival of existing neurons after CHI. In addition, engrafted iNSCs decreased immune cell recruitment and pro-inflammatory cytokine expression in the brain post-injury. Moreover, we found significant nuclear factor-kappaB (NF-κB) inhibition in the presence of iNSC grafts. In short, iNSCs exert neurotrophic and immunomodulatory effects that mitigate CHI-induced neurological impairment.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Closed head injury; Immunomodulation; Induced neural stem cell; Neuroinflammation; Neurotrophy

Mesh:

Substances:

Year:  2017        PMID: 28743043     DOI: 10.1016/j.scr.2017.07.015

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  6 in total

Review 1.  Stem Cell Therapies for Progressive Multiple Sclerosis.

Authors:  Jayden A Smith; Alexandra M Nicaise; Rosana-Bristena Ionescu; Regan Hamel; Luca Peruzzotti-Jametti; Stefano Pluchino
Journal:  Front Cell Dev Biol       Date:  2021-07-09

Review 2.  Neural stem cell derived extracellular vesicles: Attributes and prospects for treating neurodegenerative disorders.

Authors:  Andrew D Vogel; Raghavendra Upadhya; Ashok K Shetty
Journal:  EBioMedicine       Date:  2018-11-22       Impact factor: 11.205

3.  Xeno- and transgene-free reprogramming of mesenchymal stem cells toward the cells expressing neural markers using exosome treatments.

Authors:  Luis Sebástian Alexis Valerio; Kiminobu Sugaya
Journal:  PLoS One       Date:  2020-10-13       Impact factor: 3.240

4.  Induced neural stem cells from human patient-derived fibroblasts attenuate neurodegeneration in Niemann-Pick type C mice.

Authors:  Saetbyul Hong; Seung Eun Lee; Insung Kang; Jehoon Yang; Hunnyun Kim; Jeyun Kim; Kyung Sun Kang
Journal:  J Vet Sci       Date:  2021-01       Impact factor: 1.672

5.  Intracerebroventricular Administration of hNSCs Improves Neurological Recovery after Cardiac Arrest in Rats.

Authors:  Zhuoran Wang; Jian Du; Brittany Bolduc Lachance; Conrad Mascarenhas; Junyun He; Xiaofeng Jia
Journal:  Stem Cell Rev Rep       Date:  2020-11-02       Impact factor: 6.692

6.  Neuroregeneration and functional recovery after stroke: advancing neural stem cell therapy toward clinical application.

Authors:  Yang Jiao; Yu-Wan Liu; Wei-Gong Chen; Jing Liu
Journal:  Neural Regen Res       Date:  2021-01       Impact factor: 5.135

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.